Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AXNXNYSE:GKOSNASDAQ:NARINASDAQ:TNDM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXNXAxonics$70.98$70.61$66.59▼$71.05$3.63B0.82408,371 shsN/AGKOSGlaukos$94.33-0.6%$92.61$77.10▼$163.71$5.39B0.83704,790 shs1.15 million shsNARIInari Medical$79.97$79.97$39.76▼$79.99$4.68B1.021.34 million shsN/ATNDMTandem Diabetes Care$19.83-6.8%$19.44$15.75▼$53.64$1.32B1.471.49 million shs1.59 million shs5G Stocks: The Path Forward is ProfitableEnter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXNXAxonics0.00%0.00%0.00%0.00%+5.80%GKOSGlaukos0.00%-1.97%+7.68%-13.55%-16.31%NARIInari Medical0.00%0.00%0.00%0.00%+59.94%TNDMTandem Diabetes Care0.00%-4.30%-7.68%-4.57%-61.29%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAXNXAxonicsN/AN/AN/AN/AN/AN/AN/AN/AGKOSGlaukos4.6381 of 5 stars4.43.00.04.42.82.50.6NARIInari MedicalN/AN/AN/AN/AN/AN/AN/AN/ATNDMTandem Diabetes Care4.2302 of 5 stars4.21.00.04.92.31.70.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXNXAxonics 2.00HoldN/AN/AGKOSGlaukos 2.75Moderate Buy$134.6742.76% UpsideNARIInari Medical 2.14Hold$69.22-13.44% DownsideTNDMTandem Diabetes Care 2.47Hold$35.8680.82% UpsideCurrent Analyst Ratings BreakdownLatest AXNX, TNDM, GKOS, and NARI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025TNDMTandem Diabetes CareCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$20.00 ➝ $24.005/6/2025GKOSGlaukosMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetUnderweight ➝ Underweight$110.00 ➝ $72.005/2/2025GKOSGlaukosStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$140.00 ➝ $115.005/1/2025GKOSGlaukosTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$140.00 ➝ $135.005/1/2025GKOSGlaukosStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$140.00 ➝ $115.005/1/2025GKOSGlaukosNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$176.00 ➝ $115.005/1/2025GKOSGlaukosWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$160.00 ➝ $86.005/1/2025TNDMTandem Diabetes CareCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$58.00 ➝ $59.005/1/2025TNDMTandem Diabetes CareStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$60.00 ➝ $31.005/1/2025TNDMTandem Diabetes CareWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$22.00 ➝ $20.005/1/2025TNDMTandem Diabetes CarePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$36.00 ➝ $30.00(Data available from 6/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXNXAxonics$366.38M9.90$0.13 per share561.96$12.59 per share5.64GKOSGlaukos$404.52M13.32N/AN/A$9.46 per share9.97NARIInari Medical$493.63M9.48$0.09 per share906.95$8.07 per share9.91TNDMTandem Diabetes Care$982.95M1.34N/AN/A$4.81 per share4.12Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXNXAxonics-$6.09M-$0.12N/A80.66N/A-1.31%0.36%0.31%N/AGKOSGlaukos-$134.66M-$2.37N/AN/AN/A-39.04%-16.53%-10.61%7/30/2025 (Estimated)NARIInari Medical-$1.64M-$1.35N/A727.00N/A-13.68%-10.09%-6.60%N/ATNDMTandem Diabetes Care-$222.61M-$2.78N/AN/AN/A-14.84%-44.19%-11.99%8/7/2025 (Estimated)Latest AXNX, TNDM, GKOS, and NARI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/30/2025Q1 2025GKOSGlaukos-$0.33-$0.22+$0.11-$0.32$102.78 million$106.66 million4/30/2025Q1 2025TNDMTandem Diabetes Care-$0.60-$0.67-$0.07-$1.97$220.19 million$234.42 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAXNXAxonicsN/AN/AN/AN/AN/AGKOSGlaukosN/AN/AN/AN/AN/ANARIInari MedicalN/AN/AN/AN/AN/ATNDMTandem Diabetes CareN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXNXAxonicsN/A8.166.40GKOSGlaukos0.195.544.71NARIInari MedicalN/A1.771.40TNDMTandem Diabetes Care1.292.902.32Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXNXAxonics99.48%GKOSGlaukos99.04%NARIInari Medical90.98%TNDMTandem Diabetes CareN/AInsider OwnershipCompanyInsider OwnershipAXNXAxonics1.85%GKOSGlaukos5.80%NARIInari Medical10.60%TNDMTandem Diabetes Care1.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAXNXAxonics61051.11 million50.16 millionOptionableGKOSGlaukos78057.14 million51.61 millionOptionableNARIInari Medical80058.54 million52.34 millionOptionableTNDMTandem Diabetes Care2,60066.61 million64.23 millionOptionableAXNX, TNDM, GKOS, and NARI HeadlinesRecent News About These CompaniesJefferies Financial Group Inc. Has $330,000 Stock Holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)June 1 at 4:54 AM | marketbeat.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) Receives Average Recommendation of "Hold" from AnalystsJune 1 at 1:47 AM | marketbeat.comTandem Diabetes Care (NASDAQ:TNDM) Trading Down 6.2% - Time to Sell?May 31 at 2:48 PM | marketbeat.comFinancial Contrast: Tandem Diabetes Care (NASDAQ:TNDM) and PolyPid (NASDAQ:PYPD)May 31 at 1:49 AM | americanbankingnews.comTandem Diabetes Care (TNDM) Up 6.5% Since Last Earnings Report: Can It Continue?May 30 at 12:37 PM | zacks.comTandem agrees to pay $36M to settle Roche patent litigationMay 29, 2025 | drugdeliverybusiness.comReflecting On Healthcare Technology Stocks’ Q1 Earnings: Tandem Diabetes (NASDAQ:TNDM)May 28, 2025 | msn.comNuveen Asset Management LLC Grows Stock Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)May 26, 2025 | marketbeat.comJanus Henderson Group PLC Has $1.07 Million Holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)May 26, 2025 | marketbeat.comTandem Diabetes and Roche Reach a Patent SettlementMay 26, 2025 | msn.comTandem Diabetes and Roche Reach a Patent SettlementMay 25, 2025 | insidermonkey.comDeutsche Bank AG Purchases 19,308 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)May 25, 2025 | marketbeat.comBank of America Corp DE Sells 127,904 Shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM)May 25, 2025 | marketbeat.comQuantinno Capital Management LP Has $1.86 Million Stock Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)May 24, 2025 | marketbeat.comBNP Paribas Financial Markets Reduces Stock Holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)May 24, 2025 | marketbeat.comTandem Diabetes Agrees to Pay Roche $36M in Patent Infringement DealMay 23, 2025 | marketwatch.comTandem Diabetes Care (TNDM) Settles Patent Dispute with RocheMay 23, 2025 | gurufocus.comConnective Capital Management LLC Purchases New Position in Tandem Diabetes Care, Inc. (NASDAQ:TNDM)May 23, 2025 | marketbeat.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Sold by Two Sigma Advisers LPMay 23, 2025 | marketbeat.comTandem Diabetes Care, Inc. (NASDAQ:TNDM) Shares Acquired by Two Sigma Investments LPMay 23, 2025 | marketbeat.comShould Tandem Diabetes Stock Stay in Your Portfolio Now?May 22, 2025 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeAXNX, TNDM, GKOS, and NARI Company DescriptionsAxonics NASDAQ:AXNXAxonics, Inc., a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct sales force and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.Glaukos NYSE:GKOS$94.33 -0.54 (-0.57%) Closing price 05/30/2025 03:59 PM EasternExtended Trading$94.29 -0.04 (-0.04%) As of 03:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma. The company's product pipeline includes iStent Infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company markets its products through direct sales organization, as well as through distributors in the United States and internationally. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.Inari Medical NASDAQ:NARI$79.97 0.00 (0.00%) As of 02/19/2025Inari Medical, Inc. builds minimally invasive, novel, and catheter-based mechanical thrombectomy devices and accessories for the specific disease states in the United States. The company provides ClotTriever system, which is designed to core, capture, and remove large clots from large vessels for treatment of deep vein thrombosis and peripheral thrombus; FlowTriever system, a large bore catheter-based aspiration and mechanical thrombectomy system to remove large clots from large vessels in the peripheral vasculature for treating pulmonary embolism and other complex venous thromboembolism cases; InThrill system to treat small vessel thrombosis; and LimFlow system for patients who have chronic limb-threatening ischemia with no suitable endovascular or surgical revascularization options and risk of major amputation. It serves interventional radiologists, interventional cardiologists, and vascular surgeons. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.Tandem Diabetes Care NASDAQ:TNDM$19.83 -1.45 (-6.81%) Closing price 05/30/2025 04:00 PM EasternExtended Trading$19.82 -0.01 (-0.05%) As of 03:59 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Tandem Diabetes Care, Inc., a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs, and supported blood glucose meters; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/26 - 05/30 Super Micro Computer Stock Finding Upside With NVIDIA's Blackwell Ackman Takes a Swing at Amazon — Should You? Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Intel’s Turnaround May Be the Best Bet No One’s Watching Apple’s Quiet HomePad Delay Could Be Its Loudest Move Yet Nike’s Amazon Expansion Could Signal a Turnaround in 2025 ASML Stock Might Be the Safest Chip Play at This Price Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
